Videos

At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.

Firas Baidoun, MD, discusses an abstract presented at 2023 ASCO Gastrointestinal Cancers Symposium evaluating peri-operative chemotherapy for patients with non-metastatic cholangiocarcinoma.

At the 2023 ASCO GU Cancers Symposium, Siamak Daneshmand, MD, reported interim analysis results from Cohort 3 of the phase 2 THOR-2 trial.

At the 2023 ASCO GU Cancers Symposium, Nicholas Van As, MMBCh, discusses the results from the PACE-A trial, comparing quality of life outcomes from surgery vs SBRT with localized prostate cancer.

At the 2023 ASCO GU Cancers Symposium, James Catto, MB, ChB, PhD, discusses results from Cohort 2 of a phase 2 trial evaluating erdafitinib among patients with bacillus Calmette-Guérin (BCG)-unresponsive, high risk, non-muscle-invasive...

At the 2023 ASCO GU Cancers Symposium, Daniel Geynisman, MD, shares results of a trial examining a risk-adapted approach to treatment for patients with muscle-invasive bladder cancer.

At the 2023 ASCO GU Cancers Symposium, Srikala Sridhar, MD, shares results and insights from the long-term follow-up of the JAVELIN Bladder 001 trial.

At 2023 ASCO Genitourinary Cancers Symposium, Gwenaelle Gravis, MD, presented a study evaluating the addition of apalutamide to active surveillance for patients with low to intermediate risk prostate cancer.

At 2023 ASCO Genitourinary Cancers Symposium, Eleni Efstathiou, MD, shared phase 3 data which support the use of niraparib with abiraterone acetate and prednisone among patients with metastatic castration-resistant prostate cancer and BRCA...

At the 2023 ESMO Gynecological Cancers Congress, Mansoor Raza Mirza, MD, discusses the role of HER2, p53, and other molecular targets in treating patients with recurrent, metastatic endometrial cancer.